Terms: = Cervical cancer AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Treatment
11 results:
1. Integrated In-Silico and In Vitro analysis to Decipher the contribution of bisphenol-A in cervical cancer.
Khan NG; Adiga D; Rai PS; Kabekkodu SP
Toxicology; 2024 May; 504():153791. PubMed ID: 38555994
[TBL] [Abstract] [Full Text] [Related]
2. Genomic Correlates of Unfavorable Outcome in Locally Advanced cervical cancer Treated with Neoadjuvant Chemoradiation.
Wei Y; Wei C; Chen L; Liu N; Ou Q; Yin JC; Pang J; Fang Z; Wu X; Wang X; Mu D; Shao Y; Yu J; Yuan S
Cancer Res Treat; 2022 Oct; 54(4):1209-1218. PubMed ID: 35038823
[TBL] [Abstract] [Full Text] [Related]
3. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
Yoshimoto Y; Sasaki Y; Murata K; Noda SE; Miyasaka Y; Hamamoto J; Furuya M; Hirato J; Suzuki Y; Ohno T; Tokino T; Oike T; Nakano T
Gynecol Oncol; 2020 Nov; 159(2):546-553. PubMed ID: 32951893
[TBL] [Abstract] [Full Text] [Related]
4. FGFR Signaling as a Candidate Therapeutic Target for cancers Resistant to Carbon Ion Radiotherapy.
Darwis NDM; Nachankar A; Sasaki Y; Matsui T; Noda SE; Murata K; Tamaki T; Ando K; Okonogi N; Shiba S; Irie D; Kaminuma T; Kumazawa T; Anakura M; Yamashita S; Hirakawa T; Kakoti S; Hirota Y; Tokino T; Iwase A; Ohno T; Shibata A; Oike T; Nakano T
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540114
[TBL] [Abstract] [Full Text] [Related]
5. [treatment costs of malignant cervical cancer in Poland in 2011-2012--the case of Silesian Voivodeship].
Holecki T; Sobczyk K; Nawrocki S; Woźniak-Holecka J; Skrzypek M; Bocionek A
Ginekol Pol; 2015 Nov; 86(11):849-55. PubMed ID: 26817317
[TBL] [Abstract] [Full Text] [Related]
6. Genomic landscape of human papillomavirus-associated cancers.
Rusan M; Li YY; Hammerman PS
Clin Cancer Res; 2015 May; 21(9):2009-19. PubMed ID: 25779941
[TBL] [Abstract] [Full Text] [Related]
7. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
Meyer AN; McAndrew CW; Donoghue DJ
Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
[TBL] [Abstract] [Full Text] [Related]
8. [Clinical effects of combination chemotherapy with irinotecan hydrochloride and cisplatin on cervical cancer: study of 46 patients].
Wang CY; Ma D; Zhu T; Chen SY; Zhang QH; Song XJ; Chen TH; Gu MJ
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2104-8. PubMed ID: 16313818
[TBL] [Abstract] [Full Text] [Related]
9. Cell responses to fgfr3 signalling: growth, differentiation and apoptosis.
L'Hôte CG; Knowles MA
Exp Cell Res; 2005 Apr; 304(2):417-31. PubMed ID: 15748888
[TBL] [Abstract] [Full Text] [Related]
10. Clinicophathologic characteristics and treatment of small cell carcinoma of uterine cervix.
Yu A; Zhang P; Lou H
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):400-3. PubMed ID: 12408776
[TBL] [Abstract] [Full Text] [Related]
11. Neoadjuvant chemotherapy followed by radical hysterectomy and postoperative adjuvant chemotherapy in the treatment of carcinoma of the cervix uteri: long-term follow-up of a pilot study.
Sananes C; Giaroli A; Soderini A; Guardado N; Snaidas L; Bermudez A; Ferreira M; di Paola G; Sardi J
Eur J Gynaecol Oncol; 1998; 19(4):368-73. PubMed ID: 9744728
[TBL] [Abstract] [Full Text] [Related]
